CAMARCO
27.3.2024 09:01:28 CET | Business Wire | Press release
Deroma, the world’s largest Terracotta producer, together with Njord Partners, today announce the appointment of Stefano Mele as CEO of Deroma, effective from 4 March 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327185499/en/
Stefano is a highly experienced business leader in Italy, focused on the manufacturing and industrial sectors where he has a track record of delivering successful growth strategies. Stefano’s diverse background spans various sectors, from textiles and ceramics to machines and printing. As a proven leader, he has held key roles as CEO and Managing Director in international companies and business units.
Stefano has most recently been CEO of Ceramica Dolomite, an Italian bathroom sanitaryware manufacturer specialized in ceramics with 360 employees. In less than two years, he has transformed the company, which was earmarked for closure, by relaunching the commercial production of the company, creating 7 new product series in one year and developing collaboration with other sanitaryware manufacturers to facilitate reshoring their production. Before this, Stefano was CEO of Fabbri Group, an Italian fresh food packaging designer and producer.
Stefano’s multi-lingual skills and extensive international experience spanning Europe, North and South America, India and China will be invaluable for Deroma’s global expansion.
Stefano Mele, incoming CEO, commented: “I am excited to join Deroma as CEO. I hope to use my proven leadership skills and industry expertise to drive the next phase of Deroma’s growth, working together with the whole Deroma team to produce outstanding products based on the legacy of craftmanship developed over almost 70 years. I look forward to working closely with Njord Partners to deliver on this incredible opportunity.”
Arvid Trolle, Partner at Njord Partners, said: “Stefano is a world-class leader and he will be instrumental in our exciting plans to double the size of the business and further expand globally. Stefano’s experience across the wider ceramics industry will enable Deroma to fuel the gardening passion of millions of people with the continued pursuit of the highest quality Terracotta, plastic and glazed pots.”
About Stefano Mele
Stefano began his career in 1990 as a Project Engineer at Alcatel. He went on to hold management positions at Nuova Fima, Viappiani Printong, SIAT and GEA Group. Most recently, he was CEO of Fabbri Group (2019-2022) where he achieved double-digit increases in both turnover and EBITDA through entering new markets and launching a new range of environmentally sustainable products and integrated software solutions. Since 2022, Stefano has been the CEO of Ceramica Dolomite where he has relaunched their commercial production, creating seven new product series in less than two years.
About Deroma
Deroma Group is the largest Terracotta producer globally and is headquartered in Italy. Deroma produces in Europe and the United States and operates globally, with recent expansion in the UK, Asia Pacific and Eastern Europe. As a global leader in high-end garden products, Deroma also designs and distributes pots and vases made of plastic, glazed and other materials. Deroma was successfully acquired by Njord Partners in June 2021.
To find out more visit: https://deroma.com
About Njord Partners
Njord Partners is a special situations investment manager and provider of long-term flexible capital solutions. Established in 2013, Njord Partners manages capital in excess of €1 billion. Investing in European middle-market companies facing complex situations. Its mission is to deliver superior risk-weighted returns to investors while preserving capital. As a capital partner, Njord Partners offers flexible debt and equity solutions, actively facilitating strategic and operational enhancements within its portfolio companies to drive value, with a particular focus on existing debt securities and structures.
To find out more visit: https://njordpartners.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327185499/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom